To address this gap, we conducted a systematic review and meta-analysis of large RCTs to assess whether PCSK9 inhibitor therapy can reduce the risk of SCD and ventricular arrhythmias. This evidence concerns the gene PCSK9 and Ventricular arrhythmia.